Limits...
Modified weekly cisplatin-based chemotherapy is acceptable in postoperative concurrent chemoradiotherapy for locally advanced head and neck cancer.

Lu HJ, Yang CC, Wang LW, Chu PY, Tai SK, Chen MH, Yang MH, Chang PM - Biomed Res Int (2015)

Bottom Line: Survival, compliance/adverse events, and independent prognostic factors were analyzed.The most common adverse effect was grade 3/4 mucositis (28.2%).No patient died due to protocol-related adverse effects.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology and Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan ; Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Program in Molecular Medicine, School of Life Sciences, National Yang-Ming University, Taipei, Taiwan.

ABSTRACT

Background: Triweekly cisplatin-based postoperative concurrent chemoradiotherapy (CCRT) has high intolerance and toxicities in locally advanced head and neck cancer (LAHNC). We evaluated the effect of a modified weekly cisplatin-based chemotherapy in postoperative CCRT.

Methods: A total of 117 patients with LAHNC were enrolled between December 2007 and December 2012. Survival, compliance/adverse events, and independent prognostic factors were analyzed.

Results: Median follow-up time was 30.0 (3.1-73.0) months. Most patients completed the entire course of postoperative CCRT (radiotherapy ≥ 60 Gy, 94.9%; ≥ 6 times weekly chemotherapy, 75.2%). Only 17.1% patients required hospital admission. The most common adverse effect was grade 3/4 mucositis (28.2%). No patient died due to protocol-related adverse effects. Multivariate analysis revealed the following independent prognostic factors: oropharyngeal cancer, extracapsular spread, and total radiation dose. Two-year progression-free survival and overall survival rates were 70.9% and 79.5%, respectively.

Conclusion: Modified weekly cisplatin-based chemotherapy is an acceptable regimen in postoperative CCRT for LAHNC.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier plot of overall survival. Two-year overall survival rate is 79.5%.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4352419&req=5

fig2: Kaplan-Meier plot of overall survival. Two-year overall survival rate is 79.5%.

Mentions: With the weekly chemotherapy regimen of our study, 2-year PFS and OS rates were 70.9% and 79.5%, respectively. The Kaplan-Meier plots of PFS and OS are shown in Figures 1 and 2. Although there was no control group, the results of survival do not seem inferior to those of previous studies (Table 5).


Modified weekly cisplatin-based chemotherapy is acceptable in postoperative concurrent chemoradiotherapy for locally advanced head and neck cancer.

Lu HJ, Yang CC, Wang LW, Chu PY, Tai SK, Chen MH, Yang MH, Chang PM - Biomed Res Int (2015)

Kaplan-Meier plot of overall survival. Two-year overall survival rate is 79.5%.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4352419&req=5

fig2: Kaplan-Meier plot of overall survival. Two-year overall survival rate is 79.5%.
Mentions: With the weekly chemotherapy regimen of our study, 2-year PFS and OS rates were 70.9% and 79.5%, respectively. The Kaplan-Meier plots of PFS and OS are shown in Figures 1 and 2. Although there was no control group, the results of survival do not seem inferior to those of previous studies (Table 5).

Bottom Line: Survival, compliance/adverse events, and independent prognostic factors were analyzed.The most common adverse effect was grade 3/4 mucositis (28.2%).No patient died due to protocol-related adverse effects.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology and Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan ; Faculty of Medicine, National Yang Ming University, Taipei, Taiwan ; Program in Molecular Medicine, School of Life Sciences, National Yang-Ming University, Taipei, Taiwan.

ABSTRACT

Background: Triweekly cisplatin-based postoperative concurrent chemoradiotherapy (CCRT) has high intolerance and toxicities in locally advanced head and neck cancer (LAHNC). We evaluated the effect of a modified weekly cisplatin-based chemotherapy in postoperative CCRT.

Methods: A total of 117 patients with LAHNC were enrolled between December 2007 and December 2012. Survival, compliance/adverse events, and independent prognostic factors were analyzed.

Results: Median follow-up time was 30.0 (3.1-73.0) months. Most patients completed the entire course of postoperative CCRT (radiotherapy ≥ 60 Gy, 94.9%; ≥ 6 times weekly chemotherapy, 75.2%). Only 17.1% patients required hospital admission. The most common adverse effect was grade 3/4 mucositis (28.2%). No patient died due to protocol-related adverse effects. Multivariate analysis revealed the following independent prognostic factors: oropharyngeal cancer, extracapsular spread, and total radiation dose. Two-year progression-free survival and overall survival rates were 70.9% and 79.5%, respectively.

Conclusion: Modified weekly cisplatin-based chemotherapy is an acceptable regimen in postoperative CCRT for LAHNC.

Show MeSH
Related in: MedlinePlus